









Markets
/
Stocks
/
nasdaq-gild
/

Gilead Sciences Inc

GILD



View Detailed Chart

119.595USD

+1.095+0.92%

Market hours （ET）Quotes delayed by 15 min

148.54BMarket Cap

23.54P/E TTM



Gilead Sciences Inc

119.595

+1.095+0.92%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+0.92%

5 Days

-1.54%

1 Month

+6.19%

6 Months

+14.76%

Year to Date

+29.47%

1 Year

+35.78%

View Detailed Chart

TradingKey Stock Score of Gilead Sciences Inc

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Gilead Sciences Inc's Score

Industry at a Glance

Industry Ranking

4 / 160

Overall Ranking

22 / 4623

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 30 analysts

Buy

Current Rating

127.172

Target Price

+7.88%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Gilead Sciences Inc Highlights

StrengthsRisks

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 814.79%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 814.79%.

Overvalued

The company’s latest PE is 23.40, at a high 3-year percentile range.

Fairly Valued

The company’s latest PE is 23.40, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.13B shares, increasing 0.38% quarter-over-quarter.

Held by Van Duyn Dodge & E. Morris Cox

Star Investor Van Duyn Dodge & E. Morris Cox holds 30.82M shares of this stock.

News

Why Gilead Sciences Stock Just Popped

Biopharmaceuticals stock Gilead Sciences (NASDAQ: GILD) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded the shares to a buy rating and slapped a $133 price target on the $116 stock.

The Motley FoolFri, Jul 25

Trump executive order demands pharma industry price cuts

WASHINGTON, May 12 (Reuters) - U.S. President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay that analysts and legal experts said would be difficult to implement.

ReutersTue, May 13